A new study reveals that a subtype of large B cell lymphoma kills women at a much higher rate than men, driven by instability of the X chromosome. The findings open the door to a precision therapy specifically for female patients.

The UK‑led OpenBind initiative has reached a major milestone with the release of its first publicly available dataset , a groundbreaking step toward accelerating the discovery of new medicines using artificial intelligence. The release makes high‑quality, standardised experimental data freely accessible to researchers worldwide, providing AI-ready data to address the most persistent barriers in AI‑driven therapeutic development.

In APL Bioengineering, researchers design and test a hand-held device to differentiate tumors from healthy tissue using the tissues’ mechanical properties. The probe is based on optical elastography, which combines imaging with mechanical measurements like elasticity. When compressed, tumors and healthy tissue exhibit different mechanical properties, and this can be measured by the probe. Since the probe also provides a visual of the tissue, users have another data point to differentiate the two tissue types.

J. Craig Venter, the genomicist whose work redrew the architecture of modern biology, died on 29 April 2026 in San Diego at the age of 79, following complications from treatment of a recently diagnosed cancer. Brain Health, a new peer-reviewed journal launched today by Genomic Press, publishes in its inaugural issue a scientific tribute by Dr. Julio Licinio that foregrounds a part of Venter’s legacy that other obituaries have understandably treated as background: his earliest major methodological breakthrough emerged at the National Institute of Neurological Disorders and Stroke, where he pioneered the expressed sequence tag as a route to rapidly identifying brain-expressed genes. The tribute traces an arc from that neuroscience starting point through the first complete bacterial genome, the parallel pursuit of the human sequence, large-scale ocean metagenomics, and the construction of the first cell controlled by a chemically synthesized genome.

The Laureates of the prestigious 2026 Blavatnik Awards for Young Scientists in Israel are announced today by the Blavatnik Family Foundation, the Israel Academy of Sciences and Humanities, and The New York Academy of Sciences.  Each Laureate will receive US$100,000 in prize money. The Blavatnik Awards for Young Scientists in Israel are the largest unrestricted prizes available to scientists across Israel aged 42 or younger. Now in their ninth year in Israel, the Blavatnik Awards recognize research with the potential to transform lives, advance scientific understanding, and address global challenges across disciplines. The three Laureates are: Sergey N. Semenov, PhD, a chemist at the Weizmann Institute of Science, Uri Ben-David, PhD, a cancer biologist at Tel Aviv University, and Paz Beniamini, PhD, an astrophysicist at the Open University of Israel.

Colorectal cancer (CRC) is one of the most prevalent and lethal malignancies globally, with long-term survival heavily hindered by tumor recurrence, metastasis, and therapy resistance driven by a subpopulation of cancer stem cells (CSCs). While immune checkpoint blockade has revolutionized cancer treatment, its efficacy as a monotherapy in CRC remains limited, largely due to CSC-mediated immune evasion and adaptive resistance.